Regulatory milestone Soleno Therapeutics recently secured FDA approval for the first and only therapy addressing hyperphagia in Prader-Willi syndrome as of March 2025, indicating a validated treatment pathway and established demand signals that can drive payer discussions, hospital formulary coverage, and clinician advocacy efforts.

Financial scale With a funding pool of $569 million and annual revenue in the $100–250 million range, Soleno has substantial resources to support market expansion, payer negotiations, post approval studies, and launch-related infrastructure in new or existing territories.

Therapy launch risks Multiple public signals point to ongoing legal and regulatory scrutiny around the VYKAT XR launch, including fiduciary duty investigations and securities-related lawsuits, signaling a need for diligence in risk assessment, regulatory compliance confidence, and timing considerations in future engagements.

Clinical and data positioning Active participation in industry events such as ENDO 2026 and the published focus on VYKAT XR data offers an opportunity to align with key neuroendocrine and rare-disease specialists, enabling targeted conversations with KOLs, patient advocacy groups, and specialty clinics.

Strategic alignment As a Neurocrine Biosciences company with a focused rare disease portfolio, Soleno presents a cross-industry opportunity to pursue partnerships in manufacturing optimization, real-world evidence programs, and digital health integrations leveraging their tech stack to support scalable pharmacovigilance, analytics, and commercialization workflows.